Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Interferon as Long-Term Treatment for Hepatitis C Not Effective
Newswise Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, researchers and their colleagues from nine other institutions have found in a

Delhi schoolkids made aware of hepatitis, organ donation
New Delhi (IANS): School children of Delhi were Thursday made aware of measures to combat dreaded liver disease, hepatitis, as well as the importance of organ donation in saving the lives of persons afflicted by it. Over 100 students attended the

Hepatitis C therapy useless for some
WEDNESDAY, Dec. 3 (HealthDay News) -- Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests. The study also showed a

UPDATES AND COMMENTARY RSS Feed

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

Nagoya J Med Sci 1997 Nov;60(3-4):119-27

The advantage of gastrectomized patients in management of their chronic hepatitis C.

Hayashi H, Takikawa T, Arai N, Yano M

Department of Medicine, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.

Because the majority of patients with chronic hepatitis C do not respond to interferon, alternative treatments need to be established. Several lines of evidence suggest that iron depletion is beneficial for such patients. Thus, gastrectomized patients with a reduced capacity for iron absorption might have an advantage in treatment of their liver damage over patients with intact gastrointestinal tracts. Four male gastrectomized patients had post-transfusion chronic hepatitis C. The iron load in three patients was adjusted below 10 ng/ml of serum ferritin level by phlebotomy. Subsequent interferon treatment for the four patients without iron load cleared circulating hepatitis C virus RNA in one patient only. However, serum ferritin concentrations were stabilized at low levels without maintenance phlebotomy, and sustained normalization of serum liver enzyme activities was obtained in all four patients. Similar treatments were done for 10 male patients with intact gastrointestinal tracts. The amount of removed iron from these patients was more than that from gastrectomized patients. Interferon also failed to clear circulating hepatitis C virus RNA except in one case. Low ferritin levels and sustained normalization of liver enzymes were seen in three patients. A transient elevation of ferritin levels with low enzyme activities was seen in two patients. Relapsing hepatitis was seen in five of the seven patients who needed maintenance phlebotomy due to a rebound in serum ferritin levels, probably because of active iron absorption from the intestine. Our data suggest that depletion of cytotoxic iron is a key to managing patients with chronic hepatitis C.

PMID: 9481091, UI: 98142090

table Of Contents

Hepatitis Central

http://hepatitis-central.com

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008